Insider Selling: Cerus Co. (NASDAQ:CERS) CFO Sells 31,148 Shares of Stock

Cerus Co. (NASDAQ:CERS) CFO Kevin Dennis Green sold 31,148 shares of the firm’s stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $1.50, for a total transaction of $46,722.00. Following the completion of the transaction, the chief financial officer now directly owns 935,754 shares of the company’s stock, valued at $1,403,631. This represents a 3.22 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Kevin Dennis Green also recently made the following trade(s):

• On Monday, March 3rd, Kevin Dennis Green sold 60,656 shares of Cerus stock. The shares were sold at an average price of $1.58, for a total transaction of $95,836.48.

Cerus Stock Up 1.4 %

Shares of Cerus stock opened at $1.49 on Wednesday. Cerus Co. has a 52-week low of $1.38 and a 52-week high of $2.54. The company has a 50 day moving average of $1.73 and a 200 day moving average of $1.78. The company has a quick ratio of 1.92, a current ratio of 2.59 and a debt-to-equity ratio of 1.19. The company has a market capitalization of $276.83 million, a P/E ratio of -13.55 and a beta of 1.56.

Cerus (NASDAQ:CERS) last issued its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.01). Cerus had a negative net margin of 11.60% and a negative return on equity of 40.55%. The company had revenue of $50.81 million during the quarter, compared to the consensus estimate of $50.81 million. As a group, research analysts forecast that Cerus Co. will post -0.08 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $4.00 price target on shares of Cerus in a research note on Friday, February 21st.

Institutional Trading of Cerus

Institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC lifted its position in shares of Cerus by 1.6% during the 3rd quarter. Geode Capital Management LLC now owns 4,415,453 shares of the biotechnology company’s stock worth $7,685,000 after buying an additional 69,950 shares during the last quarter. State Street Corp lifted its position in shares of Cerus by 2.2% during the 3rd quarter. State Street Corp now owns 3,738,893 shares of the biotechnology company’s stock worth $6,506,000 after buying an additional 79,505 shares during the last quarter. Barclays PLC lifted its position in shares of Cerus by 16.2% during the 3rd quarter. Barclays PLC now owns 1,575,049 shares of the biotechnology company’s stock worth $2,740,000 after buying an additional 219,755 shares during the last quarter. Stifel Financial Corp lifted its position in shares of Cerus by 12.0% during the 3rd quarter. Stifel Financial Corp now owns 264,672 shares of the biotechnology company’s stock worth $461,000 after buying an additional 28,383 shares during the last quarter. Finally, ARK Investment Management LLC lifted its position in shares of Cerus by 14.2% during the 4th quarter. ARK Investment Management LLC now owns 20,814,752 shares of the biotechnology company’s stock worth $32,055,000 after buying an additional 2,589,721 shares during the last quarter. Hedge funds and other institutional investors own 78.37% of the company’s stock.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.